Protalgine

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Protalgine

Quick Facts

Property Description
Active Ingredient Lamotrigine (INN)
Form Oral Tablet (Standard and Dispersible)
Pharmacological Class Antiepileptic Agent (Anticonvulsant)
Common Use Stabilizing Neuronal Activity
Origin Synthetic

Protalgine Identity and Pharmacological Classification

Protalgine is a prescription-only pharmaceutical preparation containing the single active ingredient Lamotrigine (INN). This medication is chemically defined as a synthetic Antiepileptic Agent, classifying it within the specialized pharmacological group of Triazine Anticonvulsants.

The identity of Protalgine is rooted in the structure of Lamotrigine, a well-characterized synthetic small molecule. Its classification as an Antiepileptic Agent defines its essential purpose: to manage neuronal hyperexcitability. It is clinically recognized for its efficacy in controlling seizure frequency. A unique differentiating factor is that Lamotrigine is generally less associated with the potent induction of liver enzymes compared to older antiepileptic drugs like Phenytoin, which can simplify the management of other medications.


Composition, Form, and General Purpose

Protalgine is supplied as an oral tablet intended to be swallowed by mouth, with forms available including standard tablets and specialized dispersible tablets, offering flexibility in administration for different patient groups. This medication is a single-ingredient product, consisting solely of the active Lamotrigine combined with a solid excipient base.

The medication's fundamental general purpose is to reduce the tendency of nerve cells in the brain to become overly active. It achieves this by acting as a neuronal stabilizer, primarily by modulating the electrical activity and chemical signaling pathways that lead to uncontrolled bursts of activity. By helping the central nervous system maintain a stable, regular rhythm, Protalgine contributes to the essential therapeutic outcome of controlling erratic nerve firing.

What side effects are possible with Protalgine?

Possible side effects and safety information

The safety profile for Protalgine (Lamotrigine) is structured according to government regulatory classifications, detailing potential adverse reactions by frequency and the body systems affected. The most serious risks are categorized separately due to their clinical significance.

Serious Adverse Reactions

Official prescribing information includes warnings about rare, but potentially life-threatening reactions. These include severe skin conditions such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), as well as a severe immune reaction known as Multiorgan Hypersensitivity Reaction (DRESS), which can affect internal organs. Additionally, Hemophagocytic Lymphohistiocytosis (HLH), a life-threatening syndrome of pathologic immune activation, is documented. The label also notes risks associated with Cardiac rhythm and conduction abnormalities and Blood Dyscrasias (severe blood disorders).

Frequency and System-Organ Effects

Adverse reactions are formally listed across several system-organ classes. Very common reactions (incidence ge 10%) often affect the Nervous System (e.g., headache, dizziness, somnolence, ataxia) and Gastrointestinal System (e.g., nausea). Skin and Subcutaneous Tissue Disorders, most commonly in the form of a non-serious rash, are also frequently observed.

Safety Considerations

The onset of nearly all cases of life-threatening rashes typically occurs within the first 2 to 8 weeks of treatment initiation. The pediatric population has a higher documented incidence of serious rash compared to adults. Caution is also specified for patients with pre-existing cardiac conduction disorders or certain structural heart diseases due to the potential for serious arrhythmias. Furthermore, the risk of serious rash may be increased when co-administered with certain other medications, such as valproate.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents define the Protalgine (Lamotrigine) overdose profile by its potential to affect the central nervous system (CNS) and the cardiovascular system. This information is derived from official prescribing documents, including the FDA’s Overdosage section.

Documented Manifestations and Severe Outcomes

Acute overdose may present with signs of CNS depression, including a decreased level of consciousness, slurred speech, and coma, alongside paradoxical neurological excitability like seizures, status epilepticus, and severe ataxia. The most serious outcomes officially reported are related to cardiotoxicity, specifically cardiac conduction abnormalities, ventricular arrhythmias, and sudden cardiovascular collapse. Additionally, the documented risk of severe systemic reactions, such as Toxic Epidermal Necrolysis or Hemophagocytic Lymphohistiocytosis, necessitates specific emergency action. Overdose effects may be increased in patients with pre-existing hepatic or renal impairment.

Mandated Emergency Action

Immediate medical attention or hospitalization is required for any suspected overdose or the onset of severe symptoms. Regulators mandate the immediate discontinuation of Protalgine at the first sign of a rash, as this may signal the onset of a life-threatening systemic hypersensitivity reaction. The management of overdose is symptomatic and supportive, as no specific antidote is known. Close monitoring is essential, particularly for signs of cardiac toxicity.

Therapeutic Uses of Protalgine

What Protalgine Treats: Main Uses and Benefits

Protalgine is generally a supportive medication used for symptom management across various functional domains. As a member of this class of supportive medicines, it is commonly used to help with discomfort and other related symptomatic issues, relevant when episodes of acute or intensified symptoms occur.


Easing Episodes of Acute Discomfort

Protalgine is used in situations involving certain distressing symptoms, particularly those associated with physical discomfort or heightened physiological activity. Common uses may include supportive relief for symptoms related to physical discomfort, cough, and manifestations that create noticeable physiological strain.

Quick Fact: Supports patients during periods of physical discomfort

This supportive action is applied in clinical settings marked by temporary physiological imbalance. Protalgine contributes to easing the overall symptom load and supports patients during difficult episodes, assisting with maintaining a sense of stability.


Managing Symptom Flares and Recurrent Patterns

Protalgine is relevant for managing symptoms that interfere with daily comfort when groups of symptoms appear suddenly or fluctuate. It is useful in scenarios where conditions are characterized by periods of heightened symptoms or episodic manifestations. The medication may assist with maintaining functional stability when symptoms become more noticeable, providing supportive relief when short-term symptomatic assistance is needed.

Regulatory References

  1. NIH MedlinePlus Drug Information on Codeine

Eligibility and Restrictions for Use

Protalgine is an analgesic drug, typically recognized in regulatory documents as an opioid combination product containing codeine. Official government regulatory agencies (such as the FDA, EMA, and Health Canada) define strict eligibility criteria for its use, primarily due to the risk of life-threatening respiratory depression associated with the codeine component.

Populations Excluded from Use (Contraindicated)

Population Group Exclusion Basis (Official Labeling)
Children Younger than 12 Risk of unpredictable opioid toxicity, especially in ultra-rapid metabolizers.
Children/Adolescents Under 18 Following tonsillectomy and/or adenoidectomy for obstructive sleep apnea.
Individuals with CYP2D6 Status Known ultra-rapid metabolizers of codeine.
Breastfeeding Women Risk of infant central nervous system depression and death (codeine passes into breast milk).
Allergic/Hypersensitive Known hypersensitivity to any of the components (codeine, paracetamol/acetaminophen, or caffeine).

Populations Requiring Restricted or Conditional Use

Use is generally discouraged or requires extreme caution for adolescents (12 to 18 years) with certain risk factors like severe lung disease or obstructive sleep apnea. Caution is also advised for patients with existing significant respiratory depression, severe asthma, gastrointestinal obstruction (e.g., paralytic ileus), and those with hepatic or renal impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The clearance and resulting exposure of Protalgine (Lamotrigine) is substantially affected by co-administration with other medicinal products, primarily through pharmacokinetic interactions that alter its metabolism.

Drug-Drug Interactions Affecting Protalgine Exposure

Interaction Type Interacting Substance Official Outcome Mechanism (Label Basis)
Increased Exposure Valproate (Valproic acid) Concentration more than doubles Inhibition of glucuronidation
Decreased Exposure Enzyme Inducers (Carbamazepine, Phenytoin) Concentration decreases by approx. 40% Induction of glucuronidation
Decreased Exposure Estrogen-Containing Oral Contraceptives Concentration decreases by approx. 50% Induction of clearance

Restrictions and Additive Effects

Coadministration with certain medicinal products is not recommended when the substance is a narrow therapeutic index Organic Cationic Transporter 2 (OCT2) substrate, as Protalgine may interfere with its clearance. A potential pharmacodynamic risk is also noted: the co-administration of Protalgine with Valproate is officially associated with an increased risk of rash. Furthermore, concomitant use with alcohol or other CNS-active agents may lead to additive sedative effects.

Population-Specific Notes

The official prescribing information indicates that dosage adjustments are required for patients with hepatic impairment, reflecting the altered management of drug clearance in this population.

Mechanism of Action

Voltage- and Use-Dependent Neuronal Stabilization

Protalgine's mechanism of action is centered on modulating the electrical excitability of nerve cells in the central nervous system, demonstrating a functional consequence through two primary pharmacodynamic domains.

The core action is the stabilization of voltage-gated sodium channels (Na^+ channels) . By preferentially binding to channels that are firing at high, repetitive frequencies (a use-dependent blockade), Protalgine restricts the rapid influx of sodium ions necessary to sustain abnormal electrical activity. This specific molecular action leads directly to the stabilization of the neuronal membrane, inhibiting the development of pathological hyperexcitability.

Suppression of Excitatory Neurotransmission

The consequence of stabilizing the presynaptic membrane is a reduction in the release of excitatory amino acids, primarily Glutamate. By limiting the high-frequency firing required to trigger neurotransmitter release, Protalgine dampens chemical over-signaling. This modulation of the Glutamatergic system reduces the excessive stimulation of neighboring neurons, resulting in the modulation of CNS electrical activity.

Dosage and Administration Information

Protalgine is administered exclusively by the oral route. The required dosing schedule is structurally dependent on the patient’s concurrent medication regimen, a core principle that dictates the entire course of use. The initial dose, subsequent dose escalation rate, and eventual maintenance dose are explicitly stratified based on whether the patient is taking medications that inhibit (like Valproate) or induce (like certain other antiepileptics) Protalgine's clearance.

Administration follows a mandatory gradual titration phase over several weeks, where the dose is increased incrementally, typically every one to two weeks, until the target maintenance range is reached. For instance, initial doses may start as low as 25 mg every other day, depending on the regimen. Maintenance dosing typically ranges between 100 mg and 500 mg daily, often taken in one or two divided doses.

Protalgine may be taken with or without food. Administration requirements are specific to the formulation: standard and Extended-Release (XR) tablets must be swallowed whole. Conversely, dispersible tablets can be swallowed, chewed, or dissolved in a small amount of liquid before immediate consumption.

For specific populations, a dose reduction is utilized in patients with moderate-to-severe hepatic impairment, while pediatric dosing is calculated based on body weight. Upon discontinuation, the dose must be gradually reduced (tapered) over a period of at least two weeks. If use is interrupted for an extended time, the initial slow titration schedule must be re-initiated.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Protalgine (Lamotrigine)


Evidence for Use in Stabilizing Neuronal Activity (Seizure Disorders)

Protalgine, which was studied in research contexts involving neuronal hyperexcitability, was evaluated in clinical trials focusing on outcomes related to symptom measurements. These studies primarily involved Randomized Controlled Trials (RCTs), where researchers observed outcomes related to episodic or acute changes in seizure patterns. Trials explored both how patients fared when Protalgine was added to their existing regimen (adjunctive therapy) and when they transitioned to using Protalgine as a single treatment (monotherapy).

Studies monitored outcomes such as the percentage change in the rate of seizure occurrence and the proportion of subjects whose seizure frequency was monitored and analyzed during the study period. Findings described patterns related to seizure occurrence measurements in the studied groups compared to placebo. Research describes short-term changes for adults converting to monotherapy. Data for certain groups, such as very young children (under two years of age) receiving adjunctive treatment for partial seizures, remain insufficient.


Evidence for Use in Managing Recurrent Patterns (Bipolar I Disorder Maintenance)

Protalgine was evaluated in long-term research exploring outcomes related to fluctuating symptom measurements for conditions presenting with cycles of stability and flare-ups, specifically Bipolar I Disorder. These studies were structured as long-term randomized controlled trials applied in research contexts involving fluctuating or unstable symptoms. The core research focus was evaluated in studies observing the time interval before the occurrence of mood episodes.

Findings describe patterns related to the measured time interval before the next mood episode, particularly for the depressive phase, in the studied groups. A key limitation is that evidence for the medicine's role in the acute management (rapid stabilization) of existing mood episodes, both mania and depression, is inconclusive. Studies reported findings that were mixed or inconsistent, meaning that certainty remains low for that specific usage scenario.


Evidence Gaps and Areas of Uncertainty

The research base highlights that follow-up durations were limited in terms of truly characterizing very long-term outcomes over a patient's lifetime. The results apply only to the populations studied, meaning that research provides context but not individual predictions, especially for groups where data are still emerging or where the evidence is based on smaller subgroups. Comparative evidence is lacking for certain conditions, and data for the youngest pediatric patients remain insufficient.

Key Studies & References

  1. Lamotrigine Tablet Prescribing Information (US FDA Approved Label)

Frequently Asked Questions (FAQ)

Common questions about Protalgine (FAQ)

Q: What is the main reason doctors prescribe Protalgine?

A: Protalgine is an antiepileptic medicine that is officially approved for two main purposes. According to the FDA, it is used to manage certain types of seizures related to epilepsy. It is also approved for the long-term maintenance treatment of adults with Bipolar I Disorder.

Q: Does Protalgine start working right away, or does it take time?

A: The medicine does not typically begin to show its full effect immediately. Official prescribing information indicates that the required treatment course involves a mandatory gradual dose titration. This means the dose must be slowly increased over several weeks to safely reach the effective maintenance level.

Q: Are there any long-term effects associated with using Protalgine?

A: Clinical studies often have limitations in thoroughly characterizing outcomes over a patient's entire lifetime. However, official safety documents detail serious risks that may occur at any time, including after prolonged use, such as severe organ hypersensitivity reactions. Awareness of all documented risks, regardless of the duration of treatment, is a key consideration.

Q: Can Protalgine cause weight gain or weight loss?

A: Official reports describe Protalgine's profile as differing from certain other bipolar disorder medications regarding potential for weight gain. However, unusual weight loss has been reported as a less common side effect.

Q: What happens if I miss a scheduled dose of Protalgine?

A: Official patient information describes that a missed single dose may be taken as soon as it is remembered, unless the next dose is due very soon. Crucially, if the use of Protalgine is interrupted for five days or more, the initial, slow titration (gradual dose increase) schedule must be completely re-initiated.

Q: Is Protalgine safe for use by older adults?

A: While geriatric-specific problems are not expected to limit the use of Protalgine, older adults are more likely to have age-related issues with the heart, kidneys, or liver. Official guidance describes that dose adjustment is often considered in the presence of existing organ impairment to manage how the body processes the medication.

Q: What are the rules about using Protalgine during pregnancy?

A: Antiepileptic drugs (AEDs) are generally advised against during pregnancy unless the potential benefit outweighs the risk. Official agencies maintain a Pregnancy Registry to specifically monitor outcomes in women exposed to Protalgine while pregnant, allowing doctors to collect and analyze data.

Q: Is Protalgine commonly used in children?

A: Yes, Protalgine is approved for the treatment of certain seizure types in children who are two years of age and older. Official guidance specifies that the appropriate dosage for children is calculated based on their body weight.

Q: Can Protalgine interact with herbal supplements?

A: While specific interactions with every herbal supplement are not listed in official documents, the drug label notes that informing a healthcare provider about all co-administered medications is part of the required risk assessment. This includes any vitamins and herbs to properly identify any potential risk for drug-herb interactions.

Q: Does Protalgine have a warning about driving or operating machinery?

A: Official patient information warns that the medication may cause side effects that impact concentration and motor skills. These can include dizziness, drowsiness (somnolence), and blurred or double vision, which could affect a person's ability to safely drive or operate complex machinery.

Q: Is Protalgine known to be addictive or habit-forming?

A: Protalgine (Lamotrigine) is not scheduled under the U.S. Controlled Substances Act. This regulatory classification indicates that the medicine is not considered a controlled drug and is not associated with a high potential for abuse or dependency.

Q: Are there any genetic factors that affect how Protalgine works for people?

A: Yes, regulatory guidance highlights a genetic risk factor related to serious skin reactions. Individuals who test positive for the genetic variation *HLA-B15:02**, which is most common in people of Asian descent, have a documented increased risk of developing severe skin rashes when treated with Protalgine.

Q: Are there different brand names for the same medicine as Protalgine?

A: Yes, the active ingredient in Protalgine is known by its generic name, Lamotrigine. This same generic medicine is sold under various other brand names internationally (e.g., Lamictal).

Q: Does Protalgine need to be adjusted if a patient has kidney problems?

A: Official guidelines indicate that a dose reduction may be required for patients with significant renal impairment, or kidney problems. This adjustment is based on how well the kidneys are functioning, measured by criteria such as creatinine clearance.

Q: How quickly does the body clear Protalgine out of its system?

A: Pharmacokinetic data from official sources indicate that the elimination half-life of Protalgine typically ranges from 22.8 to 37.4 hours in healthy adults using it alone. The half-life measures the time it takes for half of the drug to be eliminated, suggesting complete clearance takes approximately five to seven days.

Q: Is there a generic version of Protalgine available?

A: Yes. The active ingredient, Lamotrigine, has been approved by the FDA as a generic product. This means that generic versions of Protalgine are available in the approved strengths and forms.

Q: How long has Protalgine been available on the market?

A: According to official FDA approval history, the active ingredient in Protalgine, Lamotrigine, first received regulatory approval in the United States on December 27, 1994.

Q: Does Protalgine require any special monitoring or blood tests?

A: While not mandatory for all patients, healthcare providers may utilize therapeutic drug monitoring (TDM) in certain clinical situations. TDM involves measuring the level of Protalgine in the blood to help guide optimal dosing and assess potential toxicity.

Q: Can taking too much Protalgine be harmful?

A: Yes, taking more than the prescribed amount of Protalgine can be harmful and potentially fatal. Overdose can lead to serious central nervous system issues, including seizures, loss of coordination, and severe cardiac conduction delays (heart rhythm problems).

Q: Are there certain physical activities that should be limited while taking Protalgine?

A: Due to the side effect of ataxia (loss of coordination), official warnings suggest that activities requiring high levels of focus and physical precision may be difficult or risky, especially when initiating treatment. It is important for individuals to proceed with caution until they understand how the medication affects them.

Q: Is Protalgine associated with any vision or hearing changes?

A: Official reports from clinical studies list certain vision-related problems as common adverse reactions. These changes include blurred vision and diplopia (double vision). Hearing changes are not commonly listed.

Q: What happens if Protalgine is taken with vitamins or minerals?

A: Official regulatory guidance notes that informing a physician about all co-administered products is necessary for risk assessment. This precaution is necessary to ensure that the combination of Protalgine with vitamins or minerals does not lead to potential interactions that could alter the drug's effect.

Q: Is there a link between Protalgine use and mood changes?

A: Official labeling includes a warning regarding a possible link to changes in mood and behavior. This includes reports of the clinical worsening of existing symptoms, the emergence of new mood symptoms, and suicidal ideation or behaviors that may be associated with treatment.

How should Protalgine be stored and disposed of?

How to Store and Dispose of Protalgine (Lamotrigine)

Official labeling requires specific conditions for storing and discarding Protalgine tablets to maintain product stability and protect public safety.


Storage Requirements

Protalgine must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The product must be protected from excessive heat and moisture; therefore, do not store it in a bathroom. Keep the tablets in their original container and ensure the container remains tightly closed.


Child Safety and Disposal

Store this medication out of the sight and reach of children. To dispose of expired or unused Protalgine, do not throw it into household trash or flush it down the toilet or sink. Unwanted medicine must be returned to a pharmacist or a recognized collection program, following local regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Protalgine found in:

A-Z Index: